Financial Performance - The company's revenue increased by 9.1% to RMB 4,446.1 million for the year ending December 31, 2024, compared to RMB 4,076.7 million for the previous year[2]. - Gross profit rose by 3.4% to RMB 1,329.5 million, up from RMB 1,286.3 million in the prior year[2]. - EBITDA grew by 2.0% to RMB 1,105.8 million, compared to RMB 1,084.1 million for the year ending December 31, 2023[2]. - Net profit decreased by 12.6% to RMB 598.3 million, down from RMB 684.9 million in the previous year[2]. - The group's hospital business revenue reached RMB 4,322.6 million, an increase of 11.1% compared to the previous year[12]. - Outpatient service revenue increased by 20.8% to RMB 1,633.0 million, while inpatient service revenue accounted for 60.5% of total hospital business revenue[11]. - The revenue from oncology-related services rose by 10.4% to RMB 1,963.0 million, representing 44.2% of total revenue[13]. - The group's gross profit from hospital operations was RMB 1,278.4 million, maintaining a stable gross margin of 29.6%[14]. - The group completed 96,993 surgeries, a year-on-year increase of 15.8%, with surgical revenue increasing by 21.2%[12]. - The profit before tax for 2024 was RMB 750,816,000, down from RMB 856,087,000 in 2023, indicating a decrease of about 12.3%[152]. Cash Flow and Financial Position - The net cash ratio, excluding pre-tax fees and payables related to acquired hospitals, improved to 137.2%, an increase of 22.9 percentage points from 114.3% in the same period last year[3]. - As of December 31, 2024, the group's cash and cash equivalents totaled RMB 369.1 million, with structured deposits and financial products amounting to RMB 282.5 million, totaling RMB 651.6 million[66]. - The net cash inflow from operating activities decreased by 9.7% from RMB 782.8 million for the year ended December 31, 2023, to RMB 707.1 million for the year ended December 31, 2024[67]. - The net cash used in investing activities decreased by 76.6% from RMB 2,863.5 million to RMB 671.1 million, primarily due to a reduction in payments for acquiring subsidiaries by RMB 1,755.8 million[68]. - Total assets increased by 1.8% from RMB 10,734.6 million to RMB 10,929.3 million[73]. - Total liabilities decreased by 5.0% from RMB 4,479.7 million to RMB 4,254.9 million[73]. - The company's debt-to-equity ratio stands at 36.3% as of December 31, 2024[86]. - The company's interest-bearing debt ratio is 25.4%, unchanged from 2023[85]. Operational Highlights - Patient satisfaction reached 97.03%, an increase of 0.91 percentage points from the previous year[8]. - The number of patient visits increased by 23.8% to approximately 4.5 million for the year ending December 31, 2024[9]. - The total number of medical professionals increased by 124 to 7,607, with 791 professionals promoted to higher titles, enhancing the hospital's long-term development[20]. - The online hospital registered nearly 230,000 consultations during the reporting period, showcasing the effectiveness of its internet medical services[27]. - The group has established a clinical medical research institute in collaboration with Suzhou University, furthering its research capabilities[24]. Strategic Initiatives - The company is actively exploring strategic partnerships with commercial insurance companies to enhance its medical payment system[8]. - The group is focused on strengthening oncology and related disciplines, enhancing the overall service level and competitiveness of its hospitals[15]. - The group has signed contracts with nearly 20 insurance companies, becoming a designated hospital for insurance claims and gradually launching direct compensation services[26]. - The company plans to enhance its clinical capabilities and service levels to meet the growing demand for tumor treatment, focusing on long-term brand building and operational efficiency[47]. Employee and Governance - The total employee compensation, including directors' salaries, amounted to RMB 1,456.1 million for the year ending December 31, 2024, compared to RMB 1,335.9 million for the previous year[96]. - The company has 8,169 full-time employees as of December 31, 2024, a decrease from 8,238 in the previous year[95]. - The board of directors includes a mix of executive and independent non-executive members, promoting good corporate governance[184]. - The company emphasizes transparency and integrity in its operations, with strict anti-corruption measures in place[38]. Environmental and Social Responsibility - The company has set targets for greenhouse gas emission intensity, water resource usage intensity, and energy usage intensity to improve its environmental performance by 2030[37]. - The company is committed to environmental protection as a strategic priority, utilizing standardized management to oversee resource use in its hospitals[37]. - The group actively engages in community service and medical charity activities, enhancing its brand influence and social impact[34]. Market Outlook - The tumor medical service market in China is projected to grow from RMB 495.1 billion in 2022 to RMB 768.7 billion by 2026, with a compound annual growth rate (CAGR) of 11.6%[45]. - The aging population in China is expected to reach 310 million by the end of 2024, with those aged 65 and above accounting for 15.6% of the total population, driving demand for cancer-related treatments[44].
海吉亚医疗(06078) - 2024 - 年度业绩